Mangrove Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Mangrove Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$758K	Sell	9,154 -3,764	-29%	-$302K	0.05%	154
2026 Q1	$993K	Buy	12,918 +2,331	+22%	+$182K	0.08%	114
2025 Q4	$836K	Buy	+10,587	New	+$917K	0.07%	130
2020 Q2	–	Sell	-426,162	Closed	-$17.4M	–	54
2020 Q1	$17.4M	Buy	426,162 +99,384	+30%	+$5.29M	2.39%	12
2019 Q4	$20.2M	Sell	326,778 -183,174	-36%	-$12.1M	2.95%	11
2019 Q3	$37.2M	Sell	509,952 -39,449	-7%	-$2.95M	4.5%	6
2019 Q2	$45.2M	Hold	549,401	–	–	5.11%	5
2019 Q1	$38.8M	Hold	549,401	–	–	5.18%	5
2018 Q4	$24.7M	Buy	549,401 +37,000	+7%	+$1.94M	3.29%	8
2018 Q3	$29M	Buy	512,401 +115,478	+29%	+$7.07M	1.83%	8
2018 Q2	$26.5M	Buy	396,923 +20,609	+5%	+$1.29M	1.71%	10
2018 Q1	$21.9M	Hold	376,314	–	–	1.43%	12
2017 Q4	$24.3M	Hold	376,314	–	–	3.27%	12
2017 Q3	$19.8M	Buy	376,314 +96,448	+34%	+$4.6M	3.39%	11
2017 Q2	$13.1M	Buy	279,866 +221,491	+379%	+$10.7M	2.67%	12
2017 Q1	$2.89M	Buy	+58,375	New	+$3.28M	0.66%	18

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mangrove Partners's ANIP Position: Q2 2026 in Review

Mangrove Partners reduced its ANI Pharmaceuticals (ANIP) stake by 29% in Q2 2026, selling an estimated $302K and leaving 9,154 shares worth $758K. The position accounts for 0.05% of the portfolio, ranked #154.

Mangrove Partners first reported a position in ANIP in Q1 2017 and has held it in 16 quarters since. The position peaked at $45.2M in Q2 2019. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Mangrove Partners held 9,154 shares of ANI Pharmaceuticals worth $758K as of Q2 2026.
Mangrove Partners sold 3,764 ANI Pharmaceuticals shares in Q2 2026, an estimated $302K.
ANI Pharmaceuticals made up 0.05% of Mangrove Partners's portfolio in Q2 2026, its #154 holding.
Mangrove Partners first reported a position in ANI Pharmaceuticals in Q1 2017 and has held it in 16 quarters since.
Mangrove Partners's ANI Pharmaceuticals position peaked at $45.2M in Q2 2019.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.